Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (NCT07087054)
A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors
🩺 Plain-English Summary (8th-Grade Level)
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (67 Sites)
Showing the first 25 of 67 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Yale University - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
- University of Miami — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
- Winshop Cancer Institute - Emory University — Atlanta, Georgia
- University of Iowa Health Care — Iowa City, Iowa
- University of Kentucky Medical Center — Lexington, Kentucky
- Louisiana State University Health Sciences — Metairie, Louisiana
- Henry Ford Cancer - Detroit — Detroit, Michigan
- Mayo Clinic — Rochester, Minnesota
- Icahn School of Medicine at Mount Sinai — New York, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- University of Virginia Comprehensive Cancer Center — Charlottesville, Virginia
- Medical College of Wisconcin — Milwaukee, Wisconsin
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo — Buenos Aires,
- Sanatorio Guemes — Buenos Aires,
- Centro de Endocrinologia y Diabetes Dr. A. Gutman ICM - Investigaciones — Buenos Aires,
- Instituto Médico Especializado Alexander Fleming — Buenos Aires,
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo — CABA,
- Instituto Médico de la Fundación Estudios Clínicos — Santa Fe,
- AC Camargo Cancer Center — São Paulo, Brazil
- Fundacao PIO XII - Hospital de Amor Barretos — Barretos,
📞 Contact the Study Coordinator
Phone: (833) 276-4636
Email: clinicaltrials@crinetics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoid Syndrome
Explore by condition: All Carcinoid Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.